Localized treatment	Localized treatment + systemic medication	P-value	Localized treatment + TKIs	Localized treatment + chemotherapy	P-value	Localized treatment + pemetrexed	Localized treatment + other chemotherapy	P-value
Total	n=24	n=186		n=75	n=111		n=21	n=90
Median age	57.5	56		57	57		60	56
Age, years			0.514			0.720			0.279
<65	18	154		63	91		15	76
≥65	6	32		12	20		6	14
Sex			0.411			0.026			0.469
Male	18	124		43	81		14	67
Female	6	62		32	30		7	23
Smoking status			0.230			0.003			0.123
Never	7	78		41	37		10	27
Former or current	17	108		34	74		11	63
KPS			0.227			0.298			0.538
≥70	14	131		56	75		13	62
<70	10	55		19	36		8	28
Histology			0.035			0.113			0.029
Adenocarcinoma	12	125		55	70		20	50
Squamous carcinoma	7	32		8	24		0	24
Others	5	29		12	17		1	16
Number of brain metastases			0.791			0.637			0.656
1	10	53		16	37		6	31
2–3	4	70		36	34		7	27
>3	10	63		23	40		8	32
Extracranial metastases			0.153			0.407			0.438
No	12	69		26	43		7	36
Vesical organ	8	65		25	40		7	33
Others	4	52		24	28		7	21
Brain metastases distribution			0.047			0.065			0.068
Synchronous	8	102		35	67		9	58
Heterochronous	16	84		40	44		12	32
Local treatments			0.779			0.006			0.929
WBRT	20	159		71	88		17	71
WBRT + surgery/SRS	4	27		4	23		4	19
RTOG RPA class			0.085			0.983			0.962
Class I	6	41		14	27		4	23
Class II	9	89		42	48		9	39
Class III	9	56		19	36		8	28
RTOG GPA grade			0.494			0.249			0.443
0∼1	8	36		11	25		4	21
1.5–2.5	11	121		54	67		14	53
3	3	19		7	12		2	10
3.5–4	2	10		3	7		1	6

Abbreviations: GPA, graded prognostic assessment; KPS, Karnofsky Performance Scale; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy; RPA, recursive partitioning analysis; RTOG, Radiation Therapy Oncology Group; TKIs, tyrosine kinase inhibitors.